We serve 5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine CAS:1180132-17-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine](https://a.dearchem.com/uploads/userup/0/15L1400U-4202.png)
Water:0.5% Max.
Sulfated ash:0.1% Max.
Heavy metals:10ppm Max
Total Impurity:0.2% Max.
Packing:
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Abemaciclib CAS:1231929-97-7.
Contact us for information like 5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-amine Use and application,5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-ylamine technical grade,usp/ep/jp grade.
Related News: In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells.2-Chloro-5-fluoro-4-iodopyridine manufacturer In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells.6,7-Dimethoxy-3,4-dihydroquinazoline-4-one supplier European companies are the main suppliers of specialty APIs, but due to environmental and cost pressures, APIs have begun to shift to the Asian market.Heptamethyldisilazane vendor Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.
